Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Double-blind, Triple Dummy, Placebo-controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow During a Public Speaking Test in Subjects Affected by Social Phobia.
Brief Summary: This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging readouts (i.e., WAT(Wave Analysis Technology) PET(Positron Emission Tomography)), after one or eight weeks of treatment. The effect of paroxetine alone after one or eight weeks of treatment will also be measured.


Options:
A: Inclusion Criteria:

* Male or female outpatients at least 18 years of age and not more than 65 years of age.
* Must sign the informed consent document.
* Present at Visit 1 with social anxiety disorder based on a Clinical Global Impression-Severity score of greater than or equal to 4.
* Females of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use both a reliable primary method of birth control.
* Judged to be reliable and willing to keep all appointments for clinic visits, tests, and procedures required by the protocol.

Exclusion Criteria:

* Have any comorbid Axis I disorders (such as major depression, obsessive compulsive disorder, post-traumatic stress disorder, or panic disorder), in the opinion of the investigator, if the disorder occurred within the last 6 months.
* Have had any previous or current diagnoses of bipolar disorders, schizophrenia, or other psychotic disorders.
* Have the presence of an Axis II disorder, except avoidant personality disorder.
* Have a serious medical illness.
* Have abnormal thyroid-stimulating hormone (TSH) concentrations or are taking thyroid supplements.
B: Inclusion Criteria:

* Diagnosis of Social Anxiety Disorder, generalized subtype
* LSAS total score of 70 at visits 1 and 2

Exclusion Criteria:

* Lifetime history of Bipolar disorder or Schizophrenia
* Current suicidal risk
* Current unstable medical condition
C: Inclusion Criteria:

* Age 18-25
* Primary DSM-IV Axis I diagnosis of social phobia, specific fear of public speaking
* PRCS total score: 21 or greater (1 SD above population norm of 14.2)

Exclusion Criteria:

* Current contraindications/sensitivity to quetiapine
* Current prescription of benzodiazepine, tranquilizer, or antipsychotic medication
* Current Psychotic episode
* Current Manic episode
* Current Depressive episode
* Current drug or alcohol dependence
* A patient with diabetes mellitus (DM) fulfilling one of the following criteria:

  * Unstable DM defined as enrollment glycosylated hemoglobin (HbA1c) 8.5%.
  * Admitted to hospital for treatment of DM or DM related illness within the past 12 weeks
  * Not under physician care for DM.
  * Physician responsible for patient's DM care has not indicated that the patient's DM is controlled.
D: Inclusion criteria:

* Social phobic ambulatory subjects, defined according to DSM-IV criteria.
* Must be capable of giving informed consent and can comply with the study requirements.
* Women of childbearing potential must agree to acceptable method of birth control.

Exclusion criteria:

* Primary diagnosis within the past 6 months of other psychiatric conditions such as major depression or another anxiety disorder.
* Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type.
* Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months.
* Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine).
* Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG) findings.

Answer: D